JP7362250B2 - 多発性骨髄腫におけるｍタンパク質反応の臨床評価 - Google Patents

多発性骨髄腫におけるｍタンパク質反応の臨床評価 Download PDF

Info

Publication number
JP7362250B2
JP7362250B2 JP2018545438A JP2018545438A JP7362250B2 JP 7362250 B2 JP7362250 B2 JP 7362250B2 JP 2018545438 A JP2018545438 A JP 2018545438A JP 2018545438 A JP2018545438 A JP 2018545438A JP 7362250 B2 JP7362250 B2 JP 7362250B2
Authority
JP
Japan
Prior art keywords
antibody
acid sequence
amino acid
seq
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018545438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513346A (ja
JP2019513346A5 (enExample
Inventor
ヘルトレ，シュテファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MorphoSys GmbH
Original Assignee
MorphoSys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MorphoSys GmbH filed Critical MorphoSys GmbH
Publication of JP2019513346A publication Critical patent/JP2019513346A/ja
Publication of JP2019513346A5 publication Critical patent/JP2019513346A5/ja
Priority to JP2022015613A priority Critical patent/JP7331168B2/ja
Priority to JP2023129240A priority patent/JP7557023B2/ja
Application granted granted Critical
Publication of JP7362250B2 publication Critical patent/JP7362250B2/ja
Priority to JP2024157490A priority patent/JP2024169455A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ecology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)
JP2018545438A 2016-03-04 2017-03-03 多発性骨髄腫におけるｍタンパク質反応の臨床評価 Active JP7362250B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022015613A JP7331168B2 (ja) 2016-03-04 2022-02-03 多発性骨髄腫におけるｍタンパク質反応の臨床評価
JP2023129240A JP7557023B2 (ja) 2016-03-04 2023-08-08 多発性骨髄腫におけるｍタンパク質反応の臨床評価
JP2024157490A JP2024169455A (ja) 2016-03-04 2024-09-11 多発性骨髄腫におけるｍタンパク質反応の臨床評価

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16158714.2 2016-03-04
EP16158714 2016-03-04
PCT/EP2017/055011 WO2017149122A1 (en) 2016-03-04 2017-03-03 Clinical assessment of m-protein response in multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022015613A Division JP7331168B2 (ja) 2016-03-04 2022-02-03 多発性骨髄腫におけるｍタンパク質反応の臨床評価

Publications (3)

Publication Number Publication Date
JP2019513346A JP2019513346A (ja) 2019-05-30
JP2019513346A5 JP2019513346A5 (enExample) 2020-04-02
JP7362250B2 true JP7362250B2 (ja) 2023-10-17

Family

ID=55745535

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018545438A Active JP7362250B2 (ja) 2016-03-04 2017-03-03 多発性骨髄腫におけるｍタンパク質反応の臨床評価
JP2022015613A Active JP7331168B2 (ja) 2016-03-04 2022-02-03 多発性骨髄腫におけるｍタンパク質反応の臨床評価
JP2023129240A Active JP7557023B2 (ja) 2016-03-04 2023-08-08 多発性骨髄腫におけるｍタンパク質反応の臨床評価
JP2024157490A Pending JP2024169455A (ja) 2016-03-04 2024-09-11 多発性骨髄腫におけるｍタンパク質反応の臨床評価

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022015613A Active JP7331168B2 (ja) 2016-03-04 2022-02-03 多発性骨髄腫におけるｍタンパク質反応の臨床評価
JP2023129240A Active JP7557023B2 (ja) 2016-03-04 2023-08-08 多発性骨髄腫におけるｍタンパク質反応の臨床評価
JP2024157490A Pending JP2024169455A (ja) 2016-03-04 2024-09-11 多発性骨髄腫におけるｍタンパク質反応の臨床評価

Country Status (10)

Country Link
US (3) US11618789B2 (enExample)
EP (1) EP3423498A1 (enExample)
JP (4) JP7362250B2 (enExample)
KR (1) KR102427948B1 (enExample)
CN (1) CN108699161B (enExample)
AU (2) AU2017226960B2 (enExample)
CA (1) CA3016098A1 (enExample)
IL (2) IL305540B2 (enExample)
SG (1) SG11201806214RA (enExample)
WO (1) WO2017149122A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209730A1 (en) 2018-04-24 2019-10-31 Helena Laboratories Corporation Removal of interfering factors from serum protein electrophoresis profiles
AU2019338999A1 (en) 2018-09-11 2021-03-18 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use
SG11202107319PA (en) 2019-03-15 2021-08-30 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
WO2023094696A1 (en) * 2021-11-29 2023-06-01 Morphosys Ag Methods for reducing anti-cd38 mab drug interference in serological assays

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661586A (en) 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
JP2008504221A (ja) 2003-12-17 2008-02-14 アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル（イーエヌエスエーエールエム） ＨＥＲ−２／ｎｅｕを模倣するヒト抗イディオタイプ抗体フラグメント
JP2008533977A (ja) 2005-03-23 2008-08-28 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
JP2012140446A (ja) 2005-02-15 2012-07-26 Duke Univ 抗ｃｄ１９抗体および腫瘍学における使用
JP2013542191A (ja) 2010-09-27 2013-11-21 モルフォシス・アー・ゲー 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ
JP2014504850A (ja) 2010-09-30 2014-02-27 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
JP2014509187A (ja) 2010-12-30 2014-04-17 武田薬品工業株式会社 結合抗ｃｄ３８抗体
JP2015530399A (ja) 2012-09-25 2015-10-15 モルフォシス エージー 組み合わせ及びその使用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3912610A (en) * 1974-07-23 1975-10-14 Icl Scient Method for electroquantitative determination of proteins
US4102990A (en) * 1977-12-05 1978-07-25 General Electric Company Electrophoretic assay for antigen-antibody reaction based on particle-particle coupling
US4578350A (en) * 1983-09-23 1986-03-25 Syntex (U.S.A.) Inc. Immunoassays employing protected labels
US6936464B1 (en) * 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US7348139B1 (en) * 2001-04-13 2008-03-25 The Johns Hopkins University School Of Medicine SOCS-1 gene methylation in cancer
US6902669B2 (en) 2002-09-13 2005-06-07 Fleetguard, Inc. Filter cartridge with floating seal
RS54056B1 (sr) 2004-02-06 2015-10-30 Morphosys Ag Anti-cd38 humana antitela i njihove upotrebe
MXPA06008700A (es) * 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
ES2653664T3 (es) 2005-10-12 2018-02-08 Morphosys Ag Generación y caracterización de anticuerpos terapéuticos obtenidos mediante HuCal GOLD completamente humanos específicos de CD38 humano
EP2046367A4 (en) * 2006-06-07 2009-11-11 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2696210A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
WO2010002911A2 (en) * 2008-06-30 2010-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and materials for monitoring myeloma using quantitative mass spetrometry
PL2580243T3 (pl) 2010-06-09 2020-05-18 Genmab A/S Przeciwciała przeciwko ludzkiemu CD38
EP2831237B1 (en) 2012-03-30 2017-11-29 The Board of Regents of the University of Oklahoma High molecular weight heparosan polymers and methods of production and use thereof
DK3677591T5 (da) 2013-04-29 2024-08-26 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b
SG10201803288RA (en) 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
PT3105317T (pt) 2014-02-14 2019-02-27 Cellectis Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661586A (en) 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
JP2008504221A (ja) 2003-12-17 2008-02-14 アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル（イーエヌエスエーエールエム） ＨＥＲ−２／ｎｅｕを模倣するヒト抗イディオタイプ抗体フラグメント
JP2012140446A (ja) 2005-02-15 2012-07-26 Duke Univ 抗ｃｄ１９抗体および腫瘍学における使用
JP2008533977A (ja) 2005-03-23 2008-08-28 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
JP2013542191A (ja) 2010-09-27 2013-11-21 モルフォシス・アー・ゲー 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ
JP2014504850A (ja) 2010-09-30 2014-02-27 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
JP2014509187A (ja) 2010-12-30 2014-04-17 武田薬品工業株式会社 結合抗ｃｄ３８抗体
JP2015530399A (ja) 2012-09-25 2015-10-15 モルフォシス エージー 組み合わせ及びその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｎｕｃｌ．Ｍｅｄ．Ｂｉｏｌ．，２００８，Ｖｏｌ．３５，Ｎｏ．２，ｐｐ．１５１－１５８

Also Published As

Publication number Publication date
US20240392034A1 (en) 2024-11-28
IL305540B1 (en) 2024-05-01
WO2017149122A1 (en) 2017-09-08
AU2017226960B2 (en) 2024-03-21
EP3423498A1 (en) 2019-01-09
IL305540A (en) 2023-10-01
AU2017226960A1 (en) 2018-08-09
CA3016098A1 (en) 2017-09-08
IL260750A (enExample) 2018-09-20
US20230203189A1 (en) 2023-06-29
JP2024169455A (ja) 2024-12-05
SG11201806214RA (en) 2018-08-30
JP7331168B2 (ja) 2023-08-22
JP2019513346A (ja) 2019-05-30
US20190077875A1 (en) 2019-03-14
IL260750B2 (en) 2024-02-01
US11618789B2 (en) 2023-04-04
JP7557023B2 (ja) 2024-09-26
KR20180118151A (ko) 2018-10-30
CN108699161B (zh) 2022-06-03
IL260750B1 (en) 2023-10-01
CN108699161A (zh) 2018-10-23
KR102427948B1 (ko) 2022-08-02
JP2022058881A (ja) 2022-04-12
AU2024201503A1 (en) 2024-03-28
JP2023157927A (ja) 2023-10-26
IL305540B2 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
JP7331168B2 (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
CN111630068B (zh) 抗cd47抗体及其用途
JP2020508645A (ja) 抗ｃｄ４７抗体およびその使用
JP6564435B2 (ja) アルファ４ベータ７ヘテロ二量体特異抗体の投与
JP4693392B2 (ja) キャピラリ電気泳動および免疫転位による単クローン性蛋白質の分析ならびに分類
US12306183B2 (en) Immunofixation electrophoresis method with target component on-gel immunodisplacement
EA037027B1 (ru) Применение и способ для профилактики или лечения рака желудка с использованием композиции, содержащей моноклональное прогастринсвязывающее антитело
JPWO2009133951A1 (ja) 抗汗抗原モノクローナル抗体
Lee et al. Identification of secreted and membrane-bound bat immunoglobulin using a Microchiropteran-specific mouse monoclonal antibody
CN120441707B (zh) 结合特瑞普利单抗的抗体及其用途
HK1261804B (en) Clinical assessment of m-protein response in multiple myeloma
HK1261804A1 (en) Clinical assessment of m-protein response in multiple myeloma
WO2022238459A1 (en) New humanized anti-vegfc antibodies and uses thereof
WO2018194944A1 (en) Monoclonal antibodies targeted to human taxilin alpha and methods for use of same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20210812

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220203

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220203

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220214

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220221

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220304

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220314

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230110

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230626

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231004

R150 Certificate of patent or registration of utility model

Ref document number: 7362250

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150